Background: Data on the performance and utility of rapid serological tests in infants to determine HIV exposure are unclear and in some instances contradictory. This study sought to understand the performance of rapid serological tests in high HIV burden, high Option B+ coverage settings to be used as an HIV exposure screening tool.
INTRODUCTION
Achieving elimination of mother-to-child transmission of HIV is a priority within the global HIV/AIDS community. Significant progress has been made in increasing access to antiretroviral therapy (ART) for pregnant women living with HIV as a critical step toward realizing this goal. In 2016, approximately 75% of HIV-positive pregnant women accessed antiretroviral treatment across 21 high-burden countries in sub-Saharan Africa. 1 However, global elimination of mother-to-child transmission targets are far from being met, and tens of thousands of children are newly infected annually. 1 Outcomes for HIV-positive children are substantially worse than those for HIV-positive women because only 51% of children living with HIV are on ART. 1 Access to timely diagnosis for the estimated 1.2 million HIV-exposed infants in these 21 high-burden countries remains a huge bottleneck to improving health outcomes for those who become infected. 1 Early infant diagnosis (EID) of HIV and immediate linkage to care is critical to survival. Without treatment, peak mortality for infants infected in utero or intrapartum occurs between 2 and 3 months of age, 2 and an estimated 50% of infected infants die by age 2 years. 3 Furthermore, data from sub-Saharan Africa demonstrated that early initiation on ART for HIV-positive infants significantly reduced mortality. 4, 5 In 2015, only 51% of HIV-exposed infants received a first nucleic acid-based test by 2 months of age. 1 Thus, a large proportion of HIV-exposed infants received a first nucleic acid-based test either too late or not at all. These statistics suggest that more deliberate and conscientious efforts are needed to identify HIV-exposed and HIV-infected infants for expedited linkage to care and treatment.
Provider-initiated testing and counseling is a mechanism to identify those HIV-positive children who are not retained in, or never enter, the prevention of mother-to-child transmission (PMTCT) cascade of care but present at other pediatric entry points within health care facilities. In 2010 and 2016, the WHO recommended that HIV serological assays, including rapid diagnostic tests, can be used to determine HIV exposure in an infant aged younger than 4 months, to determine HIV exposure in infants with signs or symptoms suggestive of HIV infection, to exclude infection in HIV-exposed, asymptomatic infants at 9 months of age, to identify HIV-exposed infants at 9 months of age in need of referral nucleic acid-based testing, or to ascertain HIV diagnosis in infants older than 18 months. 6, 7 Before 2010, access to nucleic acid-based testing and EID were poor. 8, 9 Rapid serological tests, already on the market and in widespread use for diagnosing adults, were considered to support the identification of HIV exposure in infants and in some settings as an aid to infant diagnosis because of easy access, decentralization of testing, and low costs. Rapid serological tests at that time were considered better than no test at all even if it was well understood that the performance for determining exposure and/or infection was suboptimal, particularly because serological tests are unable to distinguish between maternal and infant antibodies. However, as access to nucleic acid-based testing and EID continue to expand, are of good quality, and now reasonably priced, the utility and performance of rapid serological tests in infants have come into question. 1, 7, 10, 11 Data on the performance and utility of rapid serological tests in infants to determine HIV exposure and HIV infection are confusing and sometimes conflicting. 12 Furthermore, it has been suggested that the performance could be different depending on the health of the infant. 6, 7 We, therefore, sought to understand the performance of rapid serological tests to be used as a screening tool to accurately determine HIV exposure in infants presenting across the health care facility outside PMTCT and the subsequent need for referral nucleic acid-based testing.
METHODS
This was a cross-sectional prospective study of infants below the age of 2 years presenting at primary health facility entry points at 4 hospitals in Uganda. The 4 hospitals included were as follows: Mulago National Referral Hospital, St. Mary's Hospital Lacor , Mbale Regional Referral Hospital, and Mbarara Regional Referral Hospital. Infants were recruited from 6 facility entry points at each health care facility: immunization (Expanded Program on Immunization)/well-child clinic, pediatric outpatient, pediatric inpatient, nutrition ward, outreach, and PMTCT, which was the traditional EID testing setting. A statistically determined total sample size of 3600 infants aged younger than 2 years was included in the study. One hundred fifty infants were enrolled at each of the 6 entry points per hospital. Data collection occurred between September 2014 and August 2015.
Patients were systematically sampled and enrolled at each entry point. Because of low daily volumes (,16 infants/ d), consecutive enrollment was used at the nutrition and PMTCT entry points. Systematic sampling across all attending patients was used within the immunization, pediatric outpatient, pediatric inpatient, and outreach settings because of high patient volume to ensure unbiased patient selection. It was predicted that each entry point could enroll 15 infants per day per study nurse; therefore, if an entry point typically had 16-30, 31-45, or 46-60 eligible infants per day, each study nurse would enroll every other, third, or fourth infant, respectively. Study systems were put in place to ensure that no infant was enrolled at multiple entry points. The study objectives and study enrollment processes, including pre-HIV test counseling, were explained to the mother or guardian of each infant invited to participate in the study at non-PMTCT entry points before they signed a letter of informed consent.
Demographic and clinical data were collected for each infant and mother (if present) using standardized studyspecific forms and study-specific identification numbers. All enrolled infants underwent both serological and nucleic acidbased testing to determine HIV exposure and HIV infection status, respectively. Dried blood spot (DBS) specimens were collected for nucleic acid-based testing, and rapid serological tests using fresh capillary blood were conducted simultaneously for each patient. Both tests were conducted on each enrolled infant regardless of the respective results, except for infants at the PMTCT entry point who did not receive serological screening because their exposure status was already known. Health care facility staff and laboratory technicians were blinded to the test results of the other. Health care facility staff, including nurses, clinical officers, and laboratory technicians, were trained on study procedures, how to conduct DBS specimen collection, and rapid serological testing and demonstrated proficiency before study commencement.
Rapid serological testing was performed using the Alere Determine HIV-1/2 (Waltham, MA). One drop of whole blood was collected using a lancet heel stick, applied to the test strip, and tested per manufacturer's instructions. Either that same lancet heel stick or a fresh draw was used to collect an additional 3-5 drops of whole blood, which were applied to a filter paper card (Whatman 903; GE Healthcare Biosciences, Pittsburgh, PA). Specimens were dried for 4 hours or overnight at room temperature and shipped weekly for testing to the Central Public Health Laboratories in Kampala, Uganda. Dried blood spot specimens were processed and tested with the Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM 96) HIV-1 Qualitative Test (Roche Molecular Serologicals, Branchburg, NJ) according to the manufacturer's instructions.
Any infant with positive rapid serological test or nucleic acid-based test result were referred to PMTCT for posttest counseling of their mothers and inclusion in care and treatment per the national standard of care guidelines.
This study was approved by the Mildmay Uganda Research Ethics Committee, Uganda National Council for Science and Technology, Mulago Hospital Research and Ethics Committee, Institutional Review Committee at St. Mary's Hospital Lacor, and the Chesapeake Institutional Review Board in the USA.
Statistical analysis was performed with R statistical software (version 3.3.2; Free Software Foundation, Boston, MA) and GraphPad Prism (version 6.0; La Jolla, CA). Infants from similar entry points were pooled across hospitals for primary analyses. In addition, infants presenting to the PMTCT entry point did not receive a serological screen because their exposure status was already known, and thus were excluded from the analyses observing the performance of rapid serological tests to detect HIV exposure. Two-sample comparisons were performed using the nonparametric rankbased Wilcoxon-Mann-Whitney test and Fisher exact test for continuous and binary outcomes, respectively. Binomial probability confidence interval (CI)was computed using the Wilson method. 13 
RESULTS
A total of 3000 infants were enrolled at non-PMTCT facility entry points (46% female) ( Table 1 ). Approximately half of the infants included were aged 8 months or younger (49%), and 70% of infants were aged 12 months or younger. The median age at study inclusion was 9 months (interquartile range: 4-14 months). In the HIV-positive study population, 35% of infants were aged 8 months or younger, and 51% were aged 12 months or younger. The median age at study inclusion for HIV-positive infants was 12 months (interquartile range: 6-17 months). Most (78%) infants were breastfeeding at the time of testing; however, less than half (43%) of the HIV-positive infants were breastfeeding at the time of testing. Fifty-eight percent of infants had attended a health care facility at some point within the previous year for any health care services including immunization in all study groups.
Ninety-four HIV-positive infants and children were identified at the non-PMTCT facility entry points combined. Infants presenting to the PMTCT entry point did not receive a serological screen because their exposure status was already known, and thus were not included in the analyses. One infant was excluded because of an error in the nucleic acid-based early infant test that could not be repeated resulting in a total of 2999 infants with both rapid serological and nucleic acidbased test results. The sensitivity of the rapid serological test to accurately detect HIV exposure was 61.7% (95% CI: 51.1 to 71.5), whereas the specificity was 97.3% (95% CI: 96.6 to 97.8) ( Table 2 ). The positive predictive value in this population was 42.3% (95% CI: 34.0 to 51.1). Of the 137 infants with a positive rapid serological test, 79 (57.7%) were HIV negative by nucleic acid-based testing. The negative predictive value in this population was 98.7% (95% CI: 98.3 to 99.1). Of the 2862 infants with a negative rapid serological test, 36 (1.3%) were HIV positive by nucleic acid-based testing. In addition, 58% (79 of 137) infants with a positive rapid serological test were negative by nucleic acidbased testing.
We next analyzed the sensitivity of rapid serological tests to detect HIV exposure across several age ranges ( Table  3 ). The sensitivity remained less than 50% in infants aged younger than 1 year. The sensitivity increased to approximately 75%-85% between the ages of 12-24 months. Similarly, the positive predictive value of rapid serological tests was below 35% in infants aged younger than 8 months and increased to above 90% only at 1 year of age.
The median age of HIV-positive infants with a negative rapid serological test was 8.5 months, whereas the median age of HIV-positive infants with a positive rapid serological test was 14 months (Fig. 1 ) (Wilcoxon P-value = 0.0067). Although HIV-positive infants with a negative rapid serological test were significantly younger than HIV-positive infants with a positive rapid serological test, over a third (36.1%) of rapid serological test-negative, HIV-positive infants were aged 1 year or older. Furthermore, 38% of rapid serological test-positive, HIV-positive infants were aged 1 year or younger. Finally, there were no significant differences between HIV-positive infants with a positive rapid serological test and negative rapid serological test when comparing sex, breastfeeding status, or facility attendance.
Finally, although it was expected that most rapid serological test-negative, HIV-positive infants would have been from entry points providing care to sick infants, 6, 7 several were identified in healthy populations (Table 4) . A third (25 of 80) of HIV-positive infants who presented to health care facilities sick (nutrition and inpatient entry points) had a negative rapid serological test. Twenty-five percent of HIV-positive infants tested at the nutrition entry point were negative by rapid serological test (15 of 59), whereas 48% of HIV-positive infants tested at the inpatient entry points were negative by rapid serological test (10 of 21). Interestingly, 100% of HIV-positive infants tested at the outreach and immunization entry points were negative by rapid serological test (3 of 3). Last, 73% of HIV-positive infants tested at the outpatient entry point were negative by rapid serological test (8 of 11). (14) 399 (14) 21 (22) [16] [17] [18] [19] [20] 282 (9) 270 (9) 12 (13) 20-24 204 (7) 191 (7) 13 (14 
DISCUSSION
The WHO recommends that rapid serological tests can be used to determine HIV exposure in an infant aged younger than 4 months , to determine HIV exposure in infants with signs or symptoms suggestive of HIV infection, to exclude infection in HIV exposed, asymptomatic infants at 9 months of age, and to identify HIV-exposed infants at 9 months of age in need of referral nucleic acid-based testing. 6, 7 Infants with a reactive rapid serological test should then undergo nucleic acid-based polymerase chain reaction testing. Our results, however, found that this approach had an unexpectedly low sensitivity (61.7%) and a positive predictive value (42.3%). Although the population included in this study was of unknown HIV exposure, using rapid serological tests as a referral test to nucleic acid-based testing for this population per WHO guidelines would have resulted in missing approximately 38% (36 of 94) of HIV-positive infants due to having a negative rapid serological test. Interestingly, this population of rapid serological test-negative, HIV-positive infants had a median age lower than the rapid serological testpositive, HIV-positive infants, indicating that perhaps they had not yet developed their own anti-HIV antibodies. Age alone, however, could not explain the poor performance of the rapid serological tests or the lack of anti-HIV antibodies because the box plots were significantly overlapping. The sensitivity of rapid serological tests to determine which infants required referral nucleic acid-based testing improved by age; however, the sensitivity remained at or below 80% up to 2 years of age. These results were likely due to the time the infants were infected, which could not be determined within this study.
A recent systematic review and meta-analysis observed better performance of rapid serological tests to determine exposure and HIV infection; however, it is important to note that all studies on this topic were conducted before 2008. 12 Significant progress has been made in the past 10 years in PMTCT, namely the significant increase in mothers receiving lifelong ART for their own health and to reduce transmission (Option B+). 1 Expanded access to better drugs may have accounted for differences between these findings because it is possible that ART, especially when provided soon after infection, can lower viral loads, and thus antigen required to generate a robust antibody response and passive maternal antibody transfer. [14] [15] [16] [17] Likewise, the presence of antiretroviral prophylaxis in HIV-positive infants may similarly delay autologous antibody production. Maternal infections occurring late in the third trimester or during breastfeeding could also affect infant rapid serological test performance because infection would have occurred too late to allow for passive maternal antibody transfer. By contrast, however, a recent study in Kenya saw similar results to those presented here. 18 Twenty-three percent (11 of 48) of HIV-positive infants younger than 8 months had a negative rapid serological test.
Interestingly, although it was expected that most, if not all, rapid serological test-negative, HIV-positive infants would have been sick, several healthy yet HIV-positive infants had a negative rapid serological test. Our results and those from the Kenya study, however, suggest that serological testing should not be performed in symptomatic or asymptomatic infants to determine who is in need of referral nucleic acidbased testing. Doing so would unfortunately likely result in 25%-40% of HIV-positive infants being rapid serological testnegative, and thus missed for receiving a critical nucleic acidbased diagnosis and follow-up linkage to ART and care. 18 Alternatively, maternal testing should be emphasized and prioritized as a more reliable mechanism to identify HIV exposure in infants aged younger than 18 months. Known HIV-exposed infants or, on the rare occasion, infants whose exposure status cannot be ascertained through maternal testing should directly receive nucleic acid-based testing for diagnosis. Although concerns have been raised about the cost of introducing nucleic acid-based testing at age 9 or 12 months instead of serological testing, there have been recent significant decreases in the cost per test for EID. 10 When considering the proportion of HIV-positive infants who would be missed for nucleic acid-based testing, and thus potentially resulting in loss or death, the cost-effectiveness of implementing nucleic acid-based testing for all infants younger than 18 months may be high. 19, 20 This is generally due to the testing intervention having a significant impact on life expectancy of such a young population. For example, adding an additional test in the algorithm (at birth) was cost-effective. 19, 20 Furthermore, significant investments have been made to expand access to viral load testing of patients on ART essentially dwarfing the small volumes and relatively low costs required to test all HIV exposed, sick, or suspected infants using nucleic acid-based testing instead of serological testing.
Several limitations exist within this study. This study was not designed to determine the performance of serological testing to identify infants in need of referral nucleic acidbased testing in both well, asymptomatic infants compared with sick, symptomatic infants. Because of this, the sample size to observe this phenomenon in well, asymptomatic infants (those presenting at outreach and immunization entry points) was small. It is notable, however, that there were proportionally more false-negative rapid test results in healthy infants compared with those who presented sick. In addition, because we expected serological testing to successfully and consistently identify HIV exposure in infants, we did not conduct rapid serological testing for those presenting to the PMTCT entry point. Furthermore, again because we expected serological testing to successfully and consistently identify HIV exposure in infants, although we provided maternal testing services within the study, maternal test results were not recorded. We were unable, therefore, to determine how many HIV exposed yet uninfected infants were negative by rapid serological test.
These data suggest that the use of rapid serological tests and serological testing should be carefully considered before being used to determine either HIV exposure or infection in infants. As recommended by the WHO, serological assays should not be used in infants aged between 4 and 18 months to determine HIV exposure and instead should be determined through maternal HIV testing whenever possible. 7 Although rapid serological tests are significantly cheaper than nucleic acid-based testing, the focus of PMTCT and EID programs are generally to identify HIV-positive infants in need of antiretroviral treatment. Using rapid serological tests to identify infants in need of a referral nucleic acid-based test would result in a large proportion of significantly vulnerable HIV-positive infants to be missed and sent home without the necessary care and treatment. To improve identification and linkage of HIV-positive infants, nucleic acid-based testing should instead be considered in infants younger than 18 months of age. 
